<DOC>
	<DOCNO>NCT02799238</DOCNO>
	<brief_summary>This randomise , open-label , multi-centre , Phase II study patient newly diagnose glioblastoma . Up 87 patient newly diagnose glioblastoma enrol study 1:2 allocation ( standard care ( SOC ) : ALECSAT adjunct therapy SOC ) . Data 29 patient gather ongoing observational study glioblastoma patient treat accord SOC Sahlgrenska University hospital Göteborg , Sweden use historical control data combine randomised control data perform statistical analysis . Patients recruit study receive either : - ALECSAT adjunct therapy standard care newly diagnose glioblastoma ( first line therapy : Stupp regimen , follow second line therapy Investigator 's discretion ) - Standard care therapy newly diagnose glioblastoma ( first line therapy : Stupp regimen , follow second line therapy Investigator 's discretion ) .</brief_summary>
	<brief_title>Autologuos Lymphoid Effector Cells Specific Against Tumour ( ALECSAT ) Add Standard Care Patients With Glioblastoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Male female patient , age 18 70 . Histologically confirm glioblastoma ( Grade IV ) diagnosis . Eligible combined radiotherapy TMZ treatment . Patients complete partial tumour resection . For patient limited tumour volume , biopsy acceptable . WHO Performance status 02 . Body weight ≥ 40 kg ( male ) , ≥ 50 kg ( female ) . Able willing provide write informed consent comply study protocol procedure . Women childbearing potential must negative pregnancy test screen agree use acceptable method contraception trial . Prior treatment brain tumour study entry . Prior treatment temozolomide study entry . Females pregnant , plan become pregnant breastfeeding . Positive test anti human immunodeficiency virus ( HIV ) 1/2 ; HBsAg , anti HBc , antiHCV positive Treponema Pallidum test ( syphilis ) . Patients may expose West Nile virus Dengue fever virus within last 28 day prior enrolment Ebola virus within last 60 day prior enrolment exclude , unless patient test negative . Patients high incidence area Human TLymphotropic Virus ( HTLV1 ) virus parent spouse high incidence area must exclude unless test negative HTLV1 virus . Known allergy study medication . Any condition illness , opinion Investigator medical monitor , would compromise patient safety interfere evaluation safety investigational drug . Any concurrent illness may worsen cause complication connection blood donation , example uncontrolled epilepsy , cardiovascular , cerebrovascular respiratory disease . Use immunosuppressant drug exception steroid . Blood transfusion within 48 hour prior donation blood ALECSAT production . Low haemoglobin count opinion Investigator . Lymphocyte count &lt; 0.3 x 109/litre . Participation interventional clinical trial within 30 day prior inclusion . TMZ contraindication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>glioblastoma , GBM , immunotherapy , autologous lymphoid effector cell specific tumour cell , ALECSAT , Stupp regimen , TMZ , radiotherapy/TMZ</keyword>
</DOC>